ストックスクリーナーアプリを入手
2.78
1.77%
-0.05
アフターアワーズ：
2.76
-0.02
-0.72%
前日終値:
$2.83
開ける：
$2.83
24時間の取引高:
1.64M
Relative Volume:
1.49
時価総額：
$223.57M
収益：
$63.63M
当期純損益:
$10.62M
株価収益率:
55.60
EPS:
0.05
ネットキャッシュフロー:
$-8.64M
1週間 パフォーマンス:
-7.64%
1か月 パフォーマンス:
-4.47%
6か月 パフォーマンス:
+80.52%
1年 パフォーマンス:
+17.30%
1日の値動き範囲:
$2.66
$2.84
1週間の範囲:
$2.66
$3.045
52週間の値動き範囲:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
名前
Protalix BioTherapeutics Inc.
セクター
電話
972 4 988 9488
住所
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.78 | 227.59M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-17 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-04-04 | 開始されました | Rodman & Renshaw | Buy |
| 2015-04-23 | アップグレード | Jefferies | Hold → Buy |
| 2014-11-12 | 繰り返されました | R. F. Lafferty | Buy |
| 2014-01-24 | 開始されました | R. F. Lafferty | Buy |
| 2012-05-02 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-04-30 | ダウングレード | Auriga | Buy → Hold |
| 2011-10-13 | 開始されました | Morgan Joseph | Hold |
| 2011-03-17 | ダウングレード | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 繰り返されました | Oppenheimer | Outperform |
| 2010-10-14 | 繰り返されました | UBS | Buy |
| 2009-12-02 | 繰り返されました | Hapoalim | Outperform |
| 2009-09-22 | 開始されました | Canaccord Adams | Buy |
| 2009-09-02 | 開始されました | Hapoalim | Outperform |
| 2008-12-01 | 繰り返されました | Oppenheimer | Outperform |
| 2008-03-11 | 開始されました | UBS | Buy |
| 2007-11-20 | 開始されました | CIBC Wrld Mkts | Sector Outperform |
すべてを表示
Protalix BioTherapeutics Inc. (PLX) 最新ニュース
Retail Trends: Should I invest in Protalix BioTherapeutics Inc before earningsJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
MAK Capital Group (PLX) reports 4,649,599 shares, a 5.8% stake - Stock Titan
Published on: 2026-03-01 19:16:31 - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Protalix BioTherapeutics Reports First Quarter 2025 Financial an - GuruFocus
PLX Should I Buy - Intellectia AI
Protalix BioTherapeutics (NYSE:PLX) Shares Down 0.7%Time to Sell? - MarketBeat
Protalix Biotherapeutics Hits New 52-Week High of $3.19 - Markets Mojo
Is Protalix BioTherapeutics Inc a top pick in the sectorTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Published on: 2026-02-21 10:08:13 - baoquankhu1.vn
What is the PEG ratio of Protalix BioTherapeutics Inc.Earnings Trend Report & Safe Entry Trade Signal Reports - mfd.ru
Should I invest in Protalix BioTherapeutics Inc. before earnings2025 AllTime Highs & Risk Controlled Stock Pick Alerts - mfd.ru
Swing Trade: Will Protalix BioTherapeutics Inc benefit from rising consumer demandMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why Protalix BioTherapeutics Inc. stock could be next big winnerEarnings Summary Report & Safe Entry Momentum Stock Tips - mfd.ru
Shorts Report: Will Protalix BioTherapeutics Inc. (DE) stock outperform benchmarks2025 Macro Impact & Daily Risk Controlled Trade Plans - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from rising consumer demandGap Down & Short-Term Trading Alerts - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from government policy2025 Price Momentum & Weekly Momentum Stock Picks - mfd.ru
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing - TipRanks
Protalix BioTherapeutics, Inc. Announces Positive CHMP Opinion for Elfabrio® - TradingView
Why retail investors favor Protalix BioTherapeutics Inc. stockTrade Analysis Report & Risk Adjusted Swing Trade Ideas - mfd.ru
Fabry Disease Market Hits USD 1.7 Billion in 2024, Set for Strong Expansion Across the 7MM Through 2034 | DelveInsight - Barchart.com
RSI Check: Is Protalix BioTherapeutics Inc currently under institutional pressureWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Aug Patterns: Should I invest in Protalix BioTherapeutics Inc before earnings2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Protalix Biotherapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - Defense World
Protalix BioTherapeutics (NYSE:PLX) Trading Up 6.2%Here's Why - MarketBeat
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT) - Defense World
Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22 - Nasdaq
PLX: CHMP Delivers Positive Opinion - Research Tree
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
Protalix's New Dosing Regimen Recommended for Approval - Intellectia AI
Protalix (PLX) Surges 14% on Positive EMA Panel Opinion for Elfa - GuruFocus
Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha
Protalix (PLX) Gains Positive EMA Opinion for New Elfabrio Dosage - GuruFocus
Protalix Wins EMA Panel Backing for New Elfabrio Dosing - TipRanks
Protalix wins EU panel backing for expanded dosing of Fabry disease drug - Proactive financial news
Protalix BioTherapeutics Announces Positive CHMP Opinion for Elfabrio Dosing Regimen - TradingView
CHMP backs new Elfabrio regimen for Protalix (NYSE: PLX) patients - Stock Titan
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance
Market movers: Verizon, Sandisk, Protalix Biotherapeutics, American Express… - Proactive financial news
Is Protalix BioTherapeutics Inc. a strong candidate for buy and holdJuly 2025 Retail & Weekly Return Optimization Alerts - mfd.ru
Aug Summary: Should I invest in Rentokil Initial plc Depositary Receipt before earningsJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Winners Losers: Can Protalix BioTherapeutics Inc sustain its profitabilityM&A Rumor & Consistent Profit Trading Strategies - baoquankhu1.vn
Can Protalix BioTherapeutics Inc. lead its sector in growthPortfolio Performance Summary & Weekly Breakout Watchlists - bollywoodhelpline.com
Analyst Calls: Is PCG.PRH stock influenced by commodity prices2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Selloffs: What is Protalix BioTherapeutics Inc. s 5 year growth outlookJuly 2025 Earnings & Daily Profit Focused Screening - bollywoodhelpline.com
SQZ Biotechnologies (NYSE:SQZ) vs. Protalix BioTherapeutics (NYSE:PLX) Critical Review - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Protalix BioTherapeutics Inc. (PLX) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):